Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

ABSTRACT:

Purpose

Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers.

Patients and methods

This multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer. Eligibility included ovarian cancer resistant to prior platinum; breast cancer with ≥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy. Olaparib was administered at 400 mg twice per day. The primary efficacy end point was tumor response rate.

Results

A total of 298 pa

SUBMITTER: Kaufman B 

PROVIDER: S-EPMC6057749 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature